Madrigal Pharmaceuticals Inc  

(Public, NASDAQ:MDGL)   Watch this stock  
Find more results for NASDAQ:SNTA
16.00
-0.16 (-0.99%)
Dec 7 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 15.91 - 16.20
52 week 5.25 - 18.24
Open 16.20
Vol / Avg. 84,488.00/28,405.00
Mkt cap 186.97M
P/E     -
Div/yield     -
EPS -4.51
Shares 11.57M
Beta 0.35
Inst. own 53%
Nov 14, 2016
Q3 2016 Madrigal Pharmaceuticals Inc Earnings Release
Sep 9, 2016
Madrigal Pharmaceuticals Inc at Biocentury NewsMakers in the Biotech Industry
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -130.37% -135.93%
Return on average equity -142.36% -846.61%
Employees 10 -
CDP Score - -

Address

200 Barr Harbor Dr Ste 400
CONSHOHOCKEN, PA 19428-2978
United States - Map
+1-404-3809263 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Officers and directors

Keith R. Gollust Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Chen Schor President, Chief Executive Officer, Director
Age: 42
Bio & Compensation  - Reuters
Marc R. Schneebaum Chief Financial Officer, Senior Vice President
Age: 60
Bio & Compensation  - Reuters
Wendy E. Rieder Esq. Senior Vice President, General Counsel
Age: 47
Bio & Compensation  - Reuters
Richard S. Levy M.D. Director
Age: 59
Bio & Compensation  - Reuters
Scott Morenstein Director
Age: 39
Bio & Compensation  - Reuters
Paul A. Friedman M.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
Bruce Kovner Independent Director
Age: 70
Bio & Compensation  - Reuters
Donald W. Kufe M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters